News & Updates

Breakthrough COVID-19 is not uncommon following pre-exposure prophylaxis (PrEP) with tixagevimab/cilgavimab among patients with systemic autoimmune rheumatic diseases (SARDs), reports a recent study. However, most of the infections in this high-risk population are not severe.

A negative association exists between adalimumab (ADA) concentrations and markers of inflammatory disease activity in rheumatoid arthritis (RA), including interleukin 6 (IL-6), reveals a study. Notably, ADA concentrations from 5 to 7 mg/L over the dose interval seem to contribute to better disease control.

Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) who received a pulse dose of corticosteroids do not appear to have longer survival than those who received conventional nonpulse dose of corticosteroids, results of a study have shown.

In a study presented at AAAAI 2024, epinephrine in preservative-free, nasal powder formulations demonstrated superior stability and comparable plasma exposure to the EpiPen^® autoinjector, thus providing a less-invasive treatment option for severe allergic reactions including anaphylaxis.